101 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28259626	90	Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.	University Of Applied Sciences Darmstadt
15149697	10	Thiol-based SAHA analogues as potent histone deacetylase inhibitors.	Nagoya City University
15109664	4	Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia.	The University Of Tokyo
15109636	14	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides.	University College London
14643318	23	Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates.	Nagoya City University
14592473	35	Heterocyclic ketones as inhibitors of histone deacetylase.	Abbott Laboratories
12270175	13	Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).	Abbott Laboratories
27377864	55	Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.	Broad Institute Of Mit And Harvard
27186676	186	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.	West China Hospital Of Sichuan University
27142751	22	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.	China Pharmaceutical University
26996372	10	Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.	Sungkyunkwan University
26890116	30	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.	University Of Milan
27060764	30	Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.	Sungkyunkwan University
26443078	108	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.	Sichuan University
26814680	71	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.	Shenyang Pharmaceutical University
26706171	138	Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.	Shenyang Pharmaceutical University
26689485	18	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.	Orchid Chemicals & Pharmaceuticals
26741358	56	Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.	China Pharmaceutical University
26629860	58	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.	European Institute Of Oncology
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University Of Minnesota
26639764	17	Synthesis and biological activity of diisothiocyanate-derived mercapturic acids.	Wroclaw University Of Technology
26475519	40	Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.	China Pharmaceutical University
26241876	1	Triazine as a promising scaffold for its versatile biological behavior.	Thapar University
26331334	99	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.	Guangzhou Institute Of Biomedicine And Health
26086931	38	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.	Shandong University
26264503	46	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.	University Of Minnesota
26287310	87	Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.	University College London
25637120	94	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).	St. Jude Children'S Research Hospital
26035239	1	Natural Product Primary Sulfonamides and Primary Sulfamates.	Griffith University
25905694	24	Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.	Istituto Ortopedico Rizzoli (Ior)
25811792	32	Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.	Yonsei University
25800646	40	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.	Central South University
25113875	14	Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity.	Taipei Medical University
24999749	1	A potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.	University Of Oklahoma
25462271	33	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.	Shandong University
25455492	22	Aurones as histone deacetylase inhibitors: identification of key features.	University Of Geneva
25454270	82	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.	TBA
25238284	52	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.	Roche Pharmaceutical Research And Early Development
25233084	247	ST7612AA1, a thioacetate-¿(¿-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.	R&D Sigma-Tau Industrie Farmaceutiche Riunite
25218912	103	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.	Chinese Academy Of Sciences
25176189	7	Design, synthesis and biological evaluation ofß-boswellic acid based HDAC inhibitors as inducers of cancer cell death.	Csir-Indian Institute Of Integrative Medicine
24900838	30	Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.	Merck Research Laboratories
24766560	16	Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.	Taipei Medical University
24588105	56	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.	Universit£
24565573	35	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.	Universit£
24742384	90	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.	Universit£
24015327	42	Development of a chimeric c-Src kinase and HDAC inhibitor.	University Of Michigan
23368884	80	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.	Broad Institute Of Mit And Harvard
23252603	35	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.	Heinrich Heine Universit£T
23061376	63	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.	Roche R & D Center China
23009203	39	Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.	University Of Illinois At Chicago
22642300	160	Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.	Kyoto Prefectural University Of Medicine
21984958	83	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ¿F508-CFTR.	TBA
21874153	54	Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.	Broad Institute Of Harvard And Mit
18809328	64	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.	Irbm/Merck Research Laboratories
18182289	127	Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).	Merck Research Laboratories
18247554	134	Histone deacetylase inhibitors: from bench to clinic.	Menarini Ricerche
16987657	45	A series of novel, potent, and selective histone deacetylase inhibitors.	Irbm/Merck Research Laboratories
11206439	51	Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2.	Merck Research Laboratories
11206438	48	Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1.	Merck Research Laboratories
21548582	57	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.	University Of Illinois At Chicago
21634430	218	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.	S*Bio
21696956	243	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.	Broad Institute Of Harvard And Mit
21080647	27	Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.	Chroma Therapeutics
21417297	220	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.	Universita` Degli Studi Di Siena
21073160	143	Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity	TBA
19966789	40	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.	The Scripps Research Institute
20451378	107	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.	S*Bio
20381359	17	Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.	Universit£
20143778	70	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.	Curis
19906529	22	Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.	Ortho-Biotech Oncology Research & Development
19699639	58	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.	Methylgene
19359173	51	Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.	Sigma-Tau Research And Development
19441846	35	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.	Irbm/Merck Research Laboratories
19285395	66	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.	R&D Sigma-Tau
19268585	30	Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).	Merck Research Laboratories
19181524	46	N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.	S*Bio
19114304	44	SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).	Methylgene
18951790	109	SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).	Merck Research Laboratories
18672316	41	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.	Institute Of Organic Synthesis
18060775	67	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).	Merck Research Laboratories
14698179	58	Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group.	The Scripps Research Institute
14684344	49	(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.	Methylgene
29499113	77	Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.	Medical University Of South Carolina
14500743	60	Carbamoylcholine homologs: novel and potent agonists at neuronal nicotinic acetylcholine receptors.	The Danish University Of Pharmaceutical Sciences
1501121	12	Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.	Sanofi Recherche
282646	50	Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine.	TBA
17825569	48	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.	Polish Academy Of Sciences